Clinical Research Directory

Key Inclusion Criteria: * Diagnosis of congenital or acquired generalized lipodystrophy (GLD), as defined in the protocol * Presence of one or both of the following metabolic abnormalities at screening: 1. HbA1c ≥ 7% OR 2. Fasting TG ≥250 mg/dL * Generally stable diet (based on patient's recall) and medication regimen (that optimizes treatment for their metabolic disease) for at least 3 months prior to the screening visit Key Exclusion Criteria: * Treatment with metreleptin within 1 month of the screening visit * Treatment with over-the-counter or prescription medications for weight loss within 3 months prior to the screening visit * Treatment with oral glucocorticoids \>7.5 mg prednisone equivalents per day within 3 months prior to screening visit or plans to begin treatment with oral glucocorticoids \>7.5 mg prednisone equivalents per day during the study period * History of Human Immunodeficiency Virus (HIV) or HIV seropositivity at screening visit * Uncontrolled infection with hepatitis B or hepatitis C infection, or known active tuberculosis at screening * Participation in any clinical research study evaluating an Investigational product (IP) or therapy within 3 months and less than 5 half-lives of IP prior to the screening visit. * Pregnant or breast-feeding women NOTE: Other protocol defined inclusion/exclusion criteria apply.